

Supplementary Online Content

Reardon MJ, Heijmen RH, Van Mieghem NM, et al. Comparison of outcomes after transcatheter vs surgical aortic valve replacement among patients at intermediate operative risk with a history of coronary artery bypass graft surgery: a post hoc analysis of the SURTAVI randomized clinical trial. *JAMA Cardiol*. Published online June 19, 2019. doi:10.1001/jamacardio.2019.1856

eTable 1. Outcomes with *P* values of interaction of prior CABG (yes/no) and treatment (TAVR/SAVR)

eTable 2. Resource utilization

eFigure 1. Randomization and analysis populations

eFigure 2. Kaplan-Meier all-cause mortality or disabling stroke estimates

eFigure 3. New York Heart Association symptom status

eFigure 4. Aortic valve hemodynamics

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Outcomes with *P* values of interaction of prior CABG (yes/no) and treatment (TAVR/SAVR)

	Interaction of prior CABG (Yes/No) and Treatment (TAVR/SAVR) P values (Cox proportional model)	
	0-30 Days	0-12 Months
All-Cause Mortality or Disabling Stroke	0.3093	0.3504
All-Cause Mortality	0.9850	0.5446
Cardiovascular	0.9852	0.8314
Valve-Related ¹	NA	0.9994
Non-Cardiovascular	0.9993	0.9854
Reintervention	0.9911	0.7995
Surgical	0.9966	0.5403
Percutaneous	0.9998	0.9920
Neurological Events	0.3786	0.3686
All Stroke and TIA	0.9737	0.6812
All Stroke	0.7489	0.6590
Disabling Stroke	0.7248	0.4819
Ischemic	0.7988	0.7327
Hemorrhagic	0.9991	0.9374
Undetermined	NA	NA
Non-disabling Stroke	0.5616	0.9621
Ischemic	0.6074	0.6719
Hemorrhagic	NA	NA
Undetermined	0.9994	0.9968
TIA	0.9999	0.6035
Encephalopathy	0.4966	0.1984
Cerebral Infarction-Asymptomatic	NA	NA
Intracranial Hemorrhage	0.9994	0.9933
Bleed	0.4473	0.7842
Life Threatening or Disabling	0.8529	0.6970
Major Bleed	0.0347	0.0325
Major Vascular Complication	0.2006	0.2345
Acute Kidney Injury	0.9030	0.9459
Stage 1	0.4750	0.5230
Stage 2	0.9863	0.9863
Stage 3	0.9885	0.9885

Stage 2 or 3	0.9820	0.9820
MI	0.9460	0.1879
Peri-Procedural	0.9909	0.9909
Spontaneous	0.9951	0.0652
Cardiac Perforation	0.9867	0.9867
Cardiogenic Shock	0.5851	0.9464
Cardiac Tamponade	1.0000	1.0000
Valve Endocarditis	NA	0.9928
Leaflet Motion Abnormality or Valve Thrombosis	1.0000	0.9999
Valve Thrombosis	0.9993	0.9991
Valve Thrombosis (Sub-clinical)	NA	NA
Leaflet Motion Abnormality	0.9994	0.9994
MACCE²	0.9449	0.8894
MAE³	0.9731	0.3029
Aortic Valve Hospitalization	0.8092	0.9558
Permanent Pacemaker Implant⁴	0.3393	0.8589
Permanent Pacemaker Implant⁵	0.6787	0.8655
Atrial Fibrillation⁶	0.6628	0.6896
Mitral Valve Apparatus Damage	NA	NA
Procedural Conversion	0.6275	0.6275
Conversion to open surgery	0.9983	0.9983
TAVR Conversion to other Percutaneous	0.9993	0.9993
SAVR Conversion to alternate procedure	0.9994	0.9994
Aborted Procedure	0.6689	0.6689
Coronary Artery Obstruction	0.9991	0.9991

¹Valve-related death is any death caused by structural or non-structural valve dysfunction or aortic valve re-intervention.

²MACCE includes all-cause death, myocardial infarction (MI), all stroke, and reintervention.

³MAE includes all death, MI, all stroke, reintervention, cardiac perforation, cardiac tamponade, cardiogenic shock, valve malpositioning, prosthetic valve dysfunction, acute kidney injury, major vascular complication, life threatening or disabling bleed, major bleed, valve endocarditis.

⁴Subjects with pacemaker or ICD at baseline are not included. Not adjudicated by CEC.

⁵Subjects with pacemaker or ICD at baseline are included. Not adjudicated by CEC.


⁶Not adjudicated by CEC.

eTable 2. Resource utilization

	TAVR (N=136)	SAVR (N=137)	P Value
Procedure time, minutes	48.5 (34.0, 66.0) (134)	244.5 (194.5, 308.0) (136)	<0.01
Length of index hospital stay, days	4.0 (3.0, 6.0) (136)	7.0 (6.0, 11.0) (137)	<0.01
Length of ICU stay, hours	45.6 (22.6, 67.5) (118)	49.0 (28.0, 94.6) (131)	<0.01
Discharge location			<0.01
Home	91.9 (125/136)	72.3 (99/137)	
Rehabilitation clinic or skilled nursing	8.0 (11/136)	21.2 (29/137)	
Another hospital	0.0 (0/136)	4.4 (6/137)	
Other	0.0 (5/136)	1.5 (6/137)	


Data presented as median (Q1, Q3) (total no.) or percentage (no. / total no.). SD indicates standard deviation; TAVR: transcatheter aortic valve replacement; SAVR: surgical aortic valve replacement; and ICU: intensive care unit.

eFigure 1. Randomization and analysis populations




SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement; ITT = intention to treat; mITT = modified intention to treat; CABG = coronary artery bypass grafting.

eFigure 2. Kaplan-Meier all-cause mortality or disabling stroke estimates




All-cause mortality or disabling stroke at 1 year was similar following transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

eFigure 3. New York Heart Association symptom status



New York Heart Association (NYHA) symptom status was significantly better following transcatheter aortic valve replacement (TAVR) relative to surgical aortic valve replacement (SAVR) at 30 days, but similar between treatments at 1 year.

eFigure 4. Aortic valve hemodynamics



No. of patients with echo data

TAVR AVG	134	133	118	114
SAVR AVG	134	122	116	106
TAVR EOA	125	126	112	106
SAVR EOA	127	98	107	96

Aortic valve area was significantly larger and mean gradient was significantly lower following transcatheter aortic valve replacement (TAVR) relative to surgical aortic valve replacement (SAVR) at all follow-up visits ($P < 0.001$)